The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recurrent Glioblastoma Multiforme Treatment Market Research Report 2024
Synopsis
The global Recurrent Glioblastoma Multiforme Treatment market was valued at US$ 463.4 million in 2023 and is anticipated to reach US$ 699.5 million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Recurrent Glioblastoma Multiforme Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recurrent Glioblastoma Multiforme Treatment.
Report Scope
The Recurrent Glioblastoma Multiforme Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recurrent Glioblastoma Multiforme Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recurrent Glioblastoma Multiforme Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cantex Pharmaceuticals, Inc.
Cavion LLC
Celldex Therapeutics, Inc.
Coherus BioSciences, Inc.
Cortice Biosciences, Inc.
Eisai
Eli Lilly and Company
EnGeneIC Ltd
ERC Belgium SA
GenSpera, Inc.
Genzyme Corporation
GW Pharmaceuticals Plc
ImmunoCellular Therapeutics, Ltd.
Segment by Type
AU-105
Axitinib
AXL-1717
AZD-7451
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recurrent Glioblastoma Multiforme Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Recurrent Glioblastoma Multiforme Treatment market was valued at US$ 463.4 million in 2023 and is anticipated to reach US$ 699.5 million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Recurrent Glioblastoma Multiforme Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recurrent Glioblastoma Multiforme Treatment.
Report Scope
The Recurrent Glioblastoma Multiforme Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recurrent Glioblastoma Multiforme Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recurrent Glioblastoma Multiforme Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cantex Pharmaceuticals, Inc.
Cavion LLC
Celldex Therapeutics, Inc.
Coherus BioSciences, Inc.
Cortice Biosciences, Inc.
Eisai
Eli Lilly and Company
EnGeneIC Ltd
ERC Belgium SA
GenSpera, Inc.
Genzyme Corporation
GW Pharmaceuticals Plc
ImmunoCellular Therapeutics, Ltd.
Segment by Type
AU-105
Axitinib
AXL-1717
AZD-7451
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recurrent Glioblastoma Multiforme Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 AU-105
1.2.3 Axitinib
1.2.4 AXL-1717
1.2.5 AZD-7451
1.2.6 Others
1.3 Market by Application
1.3.1 Global Recurrent Glioblastoma Multiforme Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Perspective (2019-2030)
2.2 Recurrent Glioblastoma Multiforme Treatment Growth Trends by Region
2.2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Recurrent Glioblastoma Multiforme Treatment Historic Market Size by Region (2019-2024)
2.2.3 Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Region (2025-2030)
2.3 Recurrent Glioblastoma Multiforme Treatment Market Dynamics
2.3.1 Recurrent Glioblastoma Multiforme Treatment Industry Trends
2.3.2 Recurrent Glioblastoma Multiforme Treatment Market Drivers
2.3.3 Recurrent Glioblastoma Multiforme Treatment Market Challenges
2.3.4 Recurrent Glioblastoma Multiforme Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recurrent Glioblastoma Multiforme Treatment Players by Revenue
3.1.1 Global Top Recurrent Glioblastoma Multiforme Treatment Players by Revenue (2019-2024)
3.1.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Recurrent Glioblastoma Multiforme Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Recurrent Glioblastoma Multiforme Treatment Revenue
3.4 Global Recurrent Glioblastoma Multiforme Treatment Market Concentration Ratio
3.4.1 Global Recurrent Glioblastoma Multiforme Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recurrent Glioblastoma Multiforme Treatment Revenue in 2023
3.5 Recurrent Glioblastoma Multiforme Treatment Key Players Head office and Area Served
3.6 Key Players Recurrent Glioblastoma Multiforme Treatment Product Solution and Service
3.7 Date of Enter into Recurrent Glioblastoma Multiforme Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Type
4.1 Global Recurrent Glioblastoma Multiforme Treatment Historic Market Size by Type (2019-2024)
4.2 Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Type (2025-2030)
5 Recurrent Glioblastoma Multiforme Treatment Breakdown Data by Application
5.1 Global Recurrent Glioblastoma Multiforme Treatment Historic Market Size by Application (2019-2024)
5.2 Global Recurrent Glioblastoma Multiforme Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Recurrent Glioblastoma Multiforme Treatment Market Size (2019-2030)
6.2 North America Recurrent Glioblastoma Multiforme Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2019-2024)
6.4 North America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Recurrent Glioblastoma Multiforme Treatment Market Size (2019-2030)
7.2 Europe Recurrent Glioblastoma Multiforme Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2019-2024)
7.4 Europe Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size (2019-2030)
8.2 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size (2019-2030)
9.2 Latin America Recurrent Glioblastoma Multiforme Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2019-2024)
9.4 Latin America Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size (2019-2030)
10.2 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Boehringer Ingelheim GmbH
11.1.1 Boehringer Ingelheim GmbH Company Detail
11.1.2 Boehringer Ingelheim GmbH Business Overview
11.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Introduction
11.1.4 Boehringer Ingelheim GmbH Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2019-2024)
11.1.5 Boehringer Ingelheim GmbH Recent Development
11.2 Boston Biomedical, Inc.
11.2.1 Boston Biomedical, Inc. Company Detail
11.2.2 Boston Biomedical, Inc. Business Overview
11.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.2.4 Boston Biomedical, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2019-2024)
11.2.5 Boston Biomedical, Inc. Recent Development
11.3 Bristol-Myers Squibb Company
11.3.1 Bristol-Myers Squibb Company Company Detail
11.3.2 Bristol-Myers Squibb Company Business Overview
11.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Introduction
11.3.4 Bristol-Myers Squibb Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2019-2024)
11.3.5 Bristol-Myers Squibb Company Recent Development
11.4 Cantex Pharmaceuticals, Inc.
11.4.1 Cantex Pharmaceuticals, Inc. Company Detail
11.4.2 Cantex Pharmaceuticals, Inc. Business Overview
11.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.4.4 Cantex Pharmaceuticals, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2019-2024)
11.4.5 Cantex Pharmaceuticals, Inc. Recent Development
11.5 Cavion LLC
11.5.1 Cavion LLC Company Detail
11.5.2 Cavion LLC Business Overview
11.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Introduction
11.5.4 Cavion LLC Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2019-2024)
11.5.5 Cavion LLC Recent Development
11.6 Celldex Therapeutics, Inc.
11.6.1 Celldex Therapeutics, Inc. Company Detail
11.6.2 Celldex Therapeutics, Inc. Business Overview
11.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.6.4 Celldex Therapeutics, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2019-2024)
11.6.5 Celldex Therapeutics, Inc. Recent Development
11.7 Coherus BioSciences, Inc.
11.7.1 Coherus BioSciences, Inc. Company Detail
11.7.2 Coherus BioSciences, Inc. Business Overview
11.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.7.4 Coherus BioSciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2019-2024)
11.7.5 Coherus BioSciences, Inc. Recent Development
11.8 Cortice Biosciences, Inc.
11.8.1 Cortice Biosciences, Inc. Company Detail
11.8.2 Cortice Biosciences, Inc. Business Overview
11.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.8.4 Cortice Biosciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2019-2024)
11.8.5 Cortice Biosciences, Inc. Recent Development
11.9 Eisai
11.9.1 Eisai Company Detail
11.9.2 Eisai Business Overview
11.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Introduction
11.9.4 Eisai Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2019-2024)
11.9.5 Eisai Recent Development
11.10 Eli Lilly and Company
11.10.1 Eli Lilly and Company Company Detail
11.10.2 Eli Lilly and Company Business Overview
11.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Introduction
11.10.4 Eli Lilly and Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2019-2024)
11.10.5 Eli Lilly and Company Recent Development
11.11 EnGeneIC Ltd
11.11.1 EnGeneIC Ltd Company Detail
11.11.2 EnGeneIC Ltd Business Overview
11.11.3 EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Introduction
11.11.4 EnGeneIC Ltd Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2019-2024)
11.11.5 EnGeneIC Ltd Recent Development
11.12 ERC Belgium SA
11.12.1 ERC Belgium SA Company Detail
11.12.2 ERC Belgium SA Business Overview
11.12.3 ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Introduction
11.12.4 ERC Belgium SA Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2019-2024)
11.12.5 ERC Belgium SA Recent Development
11.13 GenSpera, Inc.
11.13.1 GenSpera, Inc. Company Detail
11.13.2 GenSpera, Inc. Business Overview
11.13.3 GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Introduction
11.13.4 GenSpera, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2019-2024)
11.13.5 GenSpera, Inc. Recent Development
11.14 Genzyme Corporation
11.14.1 Genzyme Corporation Company Detail
11.14.2 Genzyme Corporation Business Overview
11.14.3 Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Introduction
11.14.4 Genzyme Corporation Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2019-2024)
11.14.5 Genzyme Corporation Recent Development
11.15 GW Pharmaceuticals Plc
11.15.1 GW Pharmaceuticals Plc Company Detail
11.15.2 GW Pharmaceuticals Plc Business Overview
11.15.3 GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Introduction
11.15.4 GW Pharmaceuticals Plc Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2019-2024)
11.15.5 GW Pharmaceuticals Plc Recent Development
11.16 ImmunoCellular Therapeutics, Ltd.
11.16.1 ImmunoCellular Therapeutics, Ltd. Company Detail
11.16.2 ImmunoCellular Therapeutics, Ltd. Business Overview
11.16.3 ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Introduction
11.16.4 ImmunoCellular Therapeutics, Ltd. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2019-2024)
11.16.5 ImmunoCellular Therapeutics, Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
